@article{UBHD-69092954,
  author={Michaeli, Christoph T. and J{\"u}rges, Hendrik and Michaeli, Daniel},
  title={FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications},
  subtitle={cross sectional analysis},
  year={2023},
  pages={1-12},
  language={eng},
  issn={1756-1833},
  volume={381},
  number={Artikel-ID e073242},
  note={Gesehen am 04.07.2023},
  journal={The BMJ},
  doi={10.1136/bmj-2022-073242},
}
@article{UBHD-69267808,
  author={Michaeli, Christoph T. and Michaeli, Daniel},
  title={Partial orphan cancer drugs},
  subtitle={US food and drug administration approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending},
  year={2024},
  pages={449-457},
  language={eng},
  issn={1524-4733},
  volume={27},
  number={4},
  note={Gesehen am 28.10.2024},
  journal={Value in health},
  doi={10.1016/j.jval.2024.01.002},
}
@article{UBHD-69002312,
  author={Michaeli, Christoph T. and Michaeli, Daniel},
  title={Prostate cancer follow-up costs in Germany from 2000 to 2015},
  year={2022},
  pages={86-94},
  language={eng},
  issn={1932-2267},
  volume={16},
  number={1},
  note={Online ver{\"o}ffentlicht am 1. M{\"a}rz 2021 ; Gesehen am 04.01.2023},
  journal={Journal of cancer survivorship},
  doi={10.1007/s11764-021-01006-w},
  url={https://doi.org/10.1007/s11764-021-01006-w},
  library={UB},
}
@article{UBHD-69009998,
  author={Michaeli, Christoph T. and Michaeli, Julia and Michaeli, Daniel},
  title={Testicular cancer follow-up costs in Germany from 2000 to 2015},
  year={2021},
  pages={2249-2258},
  language={eng},
  issn={1432-1335},
  volume={147},
  number={8},
  note={Gesehen am 25.01.2023},
  journal={Journal of cancer research and clinical oncology},
  doi={10.1007/s00432-021-03643-1},
  url={https://doi.org/10.1007/s00432-021-03643-1},
  library={UB},
}
@article{UBHD-69117766,
  author={Michaeli, Daniel and Michaeli, Julia and Michaeli, Christoph T.},
  title={Advances in cancer therapy},
  subtitle={clinical benefit of new cancer drugs$deditorial},
  year={2023},
  pages={5232-5234},
  language={eng},
  issn={1945-4589},
  volume={15},
  number={12},
  note={Gesehen am 31.08.2023},
  journal={Aging},
  doi={10.18632/aging.204839},
}
@article{UBHD-69282748,
  author={Michaeli, Daniel and Michaeli, Christoph T.},
  title={Breakthrough therapy cancer drugs and indications with FDA approval},
  subtitle={development time, innovation, trials, clinical benefit, epidemiology, and price},
  year={2024},
  pages={1-9},
  language={eng},
  issn={1540-1413},
  volume={22},
  number={4},
  note={Online ver{\"o}ffentlicht: 22. April 2024 ; Gesehen am 11.12.2024},
  journal={Journal of the National Comprehensive Cancer Network},
  doi={10.6004/jnccn.2023.7110},
}
@article{UBHD-69162907,
  author={Michaeli, Daniel and Michaeli, Christoph T.},
  title={Cancer drug prices in the United States},
  subtitle={efficacy, innovation, clinical trial evidence, and epidemiology},
  year={2023},
  pages={1590-1600},
  language={eng},
  issn={1524-4733},
  volume={26},
  number={11 vom: Nov.},
  note={Online verf{\"u}gbar 28 July 2023, Version des Artikels 27 October 2023 ; Gesehen am 18.01.2024},
  journal={Value in health},
  doi={10.1016/j.jval.2023.06.020},
}
@article{UBHD-69167245,
  author={Michaeli, Daniel and Michaeli, Christoph T. and Albers, Sebastian and Michaeli, Julia},
  title={Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations},
  year={2024},
  pages={216-229},
  language={eng},
  issn={1460-2105},
  volume={116},
  number={2 vom: Feb.},
  note={Online ver{\"o}ffentlicht: 12. Oktober 2023, Artikelversion: 7. Dezember 2023 ; Gesehen am 30.01.2024},
  journal={Journal of the National Cancer Institute},
  doi={10.1093/jnci/djad212},
}
@article{UBHD-69284477,
  author={Michaeli, Daniel and Michaeli, Christoph T. and Albers, Sebastian and Michaeli, Julia},
  title={Clinical trial design and treatment effects},
  subtitle={a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications},
  year={2024},
  pages={333-341},
  language={eng},
  issn={2515-4478},
  volume={29},
  number={5 vom: Sept.},
  note={Erstmals ver{\"o}ffentlicht: 17. Mai 2024 ; Gesehen am 17.12.2024},
  journal={BMJ evidence-based medicine},
  doi={10.1136/bmjebm-2023-112544},
}
@article{UBHD-69132948,
  author={Michaeli, Daniel and Michaeli, Julia and Boch, Tobias and Michaeli, Christoph T.},
  title={Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapy},
  year={2022},
  pages={643-656},
  language={eng},
  issn={1179-1918},
  volume={42},
  number={8 vom: Aug.},
  note={Gesehen am 24.10.2023},
  journal={Clinical drug investigation},
  doi={10.1007/s40261-022-01173-3},
}
@article{UBHD-69193319,
  author={Michaeli, Daniel and Stoycheva, Sophia and Marcus, Simon Mashudu and Zhang, Wenjia and Michaeli, Julia and Michaeli, Christoph T.},
  title={Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination in South Africa},
  year={2022},
  pages={333-343},
  language={eng},
  issn={1179-1918},
  volume={42},
  number={4 vom: Apr.},
  note={Gesehen am 19.03.2024},
  journal={Clinical drug investigation},
  doi={10.1007/s40261-022-01138-6},
}
@article{UBHD-69231671,
  author={Michaeli, Daniel and Michaeli, Julia and Boch, Tobias and Michaeli, Christoph T.},
  title={Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention in Germany},
  year={2023},
  pages={683-694},
  language={eng},
  issn={1573-7241},
  volume={37},
  number={4 vom: Aug.},
  note={Online ver{\"o}ffentlicht: 11. Januar 2022 ; Gesehen am 09.07.2024},
  journal={Cardiovascular drugs and therapy},
  doi={10.1007/s10557-021-07310-y},
}
@book{UBHD-69296216,
  author={Michaeli, Daniel},
  organization={Universit{\"a}t Heidelberg},
  title={Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention},
  address={Heidelberg},
  year={2024},
  pages={98 Bl{\"a}tter},
  language={eng},
  school={Dissertation,   Ruprecht-Karls-Universit{\"a}t zu Heidelberg,  2024},
  library={UB [Signatur: 2025 U 149]},
}
@book{UBHD-69277247,
  author={Michaeli, Daniel},
  organization={Universit{\"a}t Heidelberg},
  title={Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention},
  address={Heidelberg},
  year={2024},
  pages={1 Online-Ressource (98 Seiten)},
  language={eng},
  school={Dissertation,   Ruprecht-Karls-Universit{\"a}t zu Heidelberg,  2024},
  doi={10.11588/heidok.00035637},
  url={https://nbn-resolving.de/urn:nbn:de:bsz:16-heidok-356377},
  library={UB ; UW},
}
@article{UBHD-69184501,
  author={Michaeli, Daniel and Michaeli, Julia and Albers, Sebastian and Boch, Tobias and Michaeli, Christoph T.},
  title={Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention},
  subtitle={leading article},
  year={2023},
  pages={477-495},
  language={eng},
  issn={1179-187X},
  volume={23},
  number={5 vom: Sept.},
  note={Online ver{\"o}ffentlicht: 24. Juli 2023 ; Gesehen am 21.02.2024},
  journal={American journal of cardiovascular drugs},
  doi={10.1007/s40256-023-00594-5},
}
@book{UBHD-69276804,
  author={Michaeli, Daniel and Yagmur, Hasan and Michaeli, Christoph T.},
  title={Germany's healthcare system},
  subtitle={funding, resource allocation, provider payment, efficiency, and access},
  publisher={SSRN},
  address={[S.l.]},
  year={2022},
  pages={1 Online-Ressource (14 p)},
  language={eng},
  note={Nach Informationen von SSRN wurde die urspr{\"u}ngliche Fassung des Dokuments April 1, 2022 erstellt},
  doi={10.2139/ssrn.4072939},
}
@book{UBHD-69316752,
  author={Michaeli, Daniel and Michaeli, Julia and Albers, Sebastian and Michaeli, Christoph T.},
  title={The healthcare workforce shortage of nurses and physicians},
  subtitle={practice, theory, evidence, and ways forward},
  publisher={Sage},
  address={Los Angeles},
  year={2024},
  pages={1 Online-Ressource (12 Seiten)},
  language={eng},
  note={In: Policy, Politics, & Nursing Practice, 25 (2024), Nr. 4. pp. 216-227. ISSN 1527-1544},
  doi={10.11588/heidok.00036055},
  url={https://nbn-resolving.de/urn:nbn:de:bsz:16-heidok-360554},
  library={UB},
}
@article{UBHD-69132968,
  author={Michaeli, Daniel and Mills, Mackenzie and Michaeli, Christoph T. and Miracolo, Aurelio and Kanavos, Panos},
  title={Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA},
  subtitle={phase III studies},
  year={2022},
  pages={798-809},
  language={eng},
  issn={1573-0646},
  volume={40},
  number={4 vom: Aug.},
  note={Gesehen am 24.10.2023},
  journal={Investigational new drugs},
  doi={10.1007/s10637-022-01227-5},
}
@article{UBHD-69157178,
  author={Michaeli, Daniel and Michaeli, Christoph T.},
  title={Launch and post-launch prices of injectable cancer drugs in the US},
  subtitle={clinical benefit, innovation, epidemiology, and competition},
  year={2024},
  pages={117-131},
  language={eng},
  issn={1179-2027},
  volume={42},
  number={1},
  note={Online ver{\"o}ffentlicht: 19. Oktober 2023 ; Gesehen am 04.01.2024},
  journal={PharmacoEconomics},
  doi={10.1007/s40273-023-01320-4},
}
@article{UBHD-69087585,
  author={Michaeli, Daniel and Michaeli, Christoph T.},
  title={Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021},
  year={2022},
  pages={4095-4106},
  language={eng},
  issn={1527-7755},
  volume={40},
  number={35},
  note={Gesehen am 20.06.2023},
  journal={Journal of clinical oncology},
  doi={10.1200/JCO.22.00535},
}
@article{UBHD-69265691,
  author={Michaeli, Daniel and Michaeli, Christoph T. and Albers, Sebastian and Michaeli, Julia},
  title={Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs},
  year={2024},
  pages={797-809},
  language={eng},
  issn={1776-260X},
  volume={19},
  number={5 vom: Sept.},
  note={Online ver{\"o}ffentlicht: 31. Juli 2024 ; Gesehen am 28.10.2024},
  journal={Targeted oncology},
  doi={10.1007/s11523-024-01081-w},
}
@article{UBHD-69188054,
  author={Michaeli, Daniel and Michaeli, Christoph T. and Albers, Sebastian and Boch, Tobias and Michaeli, Julia},
  title={Special FDA designations for drug development},
  subtitle={orphan, fast track, accelerated approval, priority review, and breakthrough therapy},
  year={2024},
  pages={979-997},
  language={eng},
  issn={1618-7601},
  volume={25},
  number={6 vom: Aug.},
  note={Online ver{\"o}ffentlicht: 14. November 2023 ; Gesehen am 05.03.2024},
  journal={The European journal of health economics},
  doi={10.1007/s10198-023-01639-x},
}
@article{UBHD-69209550,
  author={Michaeli, Daniel and Yagmur, Hasan Basri and Achmadeev, Timur and Michaeli, Christoph T.},
  title={Valuation and returns of drug development companies},
  subtitle={lessons for bioentrepreneurs and investors},
  year={2022},
  pages={313-322},
  language={eng},
  issn={2168-4804},
  volume={56},
  number={2 vom: M{\"a}rz},
  note={Gesehen am 29.04.2024},
  journal={Therapeutic innovation & regulatory science},
  doi={10.1007/s43441-021-00364-y},
}
@article{UBHD-69124568,
  author={Michaeli, Daniel and Mills, Mackenzie and Kanavos, Panos},
  title={Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland},
  year={2022},
  pages={757-768},
  language={eng},
  issn={1179-1896},
  volume={20},
  number={5 vom: Sept.},
  note={Gesehen am 26.09.2023},
  journal={Applied health economics and health policy},
  doi={10.1007/s40258-022-00737-w},
}
@article{UBHD-69321463,
  author={Michaeli, Daniel and Michaeli, Christoph T.},
  title={Value-based indication-specific pricing and weighted-average pricing},
  subtitle={estimated price and cost savings for cancer drugs},
  year={2025},
  pages={415-427},
  language={eng},
  issn={1179-2027},
  volume={43},
  number={4 vom: Apr.},
  note={Online ver{\"o}ffentlicht: 30. Dezember 2024 ; Gesehen am 24.03.2025},
  journal={PharmacoEconomics},
  doi={10.1007/s40273-024-01448-x},
}
@article{UBHD-69009859,
  author={Michaeli, Daniel and Yagmur, Hasan Basri and Achmadeev, Timur and Michaeli, Christoph T.},
  title={Value drivers of development stage biopharma companies},
  year={2022},
  pages={1287-1296},
  language={eng},
  issn={1618-7601},
  volume={23},
  number={8 vom: Nov.},
  journal={The European journal of health economics},
  doi={10.1007/s10198-021-01427-5},
  url={https://link.springer.com/content/pdf/10.1007/s10198-021-01427-5.pdf},
  library={UB},
}
@article{UBHD-69292904,
  author={Michaeli, Julia and Michaeli, Christoph T. and Trapani, Dario and Albers, Sebastian and Dannehl, Dominik and W{\"u}rstlein, Rachel and Michaeli, Daniel},
  title={Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price},
  year={2024},
  pages={1144-1155},
  language={eng},
  issn={1880-4233},
  volume={31},
  number={6 vom: Nov.},
  note={Online ver{\"o}ffentlicht: 25. September 2024 ; Gesehen am 21.01.2025},
  journal={Breast cancer},
  doi={10.1007/s12282-024-01634-x},
}
@article{UBHD-69234216,
  author={Michaeli, Julia and Albers, Sebastian and Torre, Carolina de la and Schreiner, Yannick and Faust, Sara and Michaeli, Christoph T. and Michaeli, Daniel and An, Liying and Kr{\"a}mer, Bernhard and Stach-Jablonski, Ksenija and Yard, Benito A.},
  title={Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells},
  year={2023},
  pages={1-11},
  language={eng},
  issn={2045-2322},
  volume={13},
  number={Artikel-ID 16159},
  note={Gesehen am 16.07.2024},
  journal={Scientific reports},
  doi={10.1038/s41598-023-43142-6},
}
@article{UBHD-69185969,
  author={Michaeli, Julia and Michaeli, Daniel and Boch, Tobias and Albers, Sebastian and Michaeli, Christoph T.},
  title={Socio-economic burden of disease: survivorship costs for renal cell carcinoma},
  year={2022},
  pages={1-11},
  language={eng},
  issn={1365-2354},
  volume={31},
  note={Erstmals ver{\"o}ffentlicht: 15. M{\"a}rz 2022 ; Gesehen am 27.02.2024},
  journal={European journal of cancer care},
  doi={10.1111/ecc.13569},
}
@article{UBHD-69065990,
  author={Mills, Mackenzie and Michaeli, Daniel and Miracolo, Aurelio and Kanavos, Panos},
  title={Launch sequencing of pharmaceuticals with multiple therapeutic indications},
  subtitle={evidence from seven countries},
  year={2023},
  pages={1-17},
  language={eng},
  issn={1472-6963},
  volume={23},
  number={Artikel-ID 150},
  note={Gesehen am 17.04.2023},
  journal={BMC health services research},
  doi={10.1186/s12913-023-09095-2},
}